Ahmedabad 18 December, 2025: India has taken a decisive step forward in advanced stroke treatment with the successful completion of the GRASSROOT Trial, a landmark multicentre clinical study evaluating the Supernova Stent Retriever for patients with acute ischemic stroke due to large vessel occlusion. This achievement marks a major milestone in India’s journey toward self-reliance in advanced neurovascular care.
At the core of this breakthrough lies the fact that “Stent design by indian engineers and study done in indian 8 hospital including cims hospital and going to make in india dream come true.” The GRASSROOT Trial was conducted across eight leading stroke centres in the country, including Marengo CIMS Hospital, providing robust Indian clinical evidence for an indigenously developed device.
Adding to its national significance, this innovation confirms that “Made in India stent now for brain vessels also in acute brain stroke.” The Supernova stent retriever has demonstrated strong safety and efficacy outcomes, offering high rates of successful vessel recanalization, favourable first-pass success, and encouraging functional recovery at 90 days, with a low complication profile.
These outcomes are comparable to global benchmarks while addressing a critical gap in accessibility and affordability. Stroke remains one of the leading causes of death and long-term disability in India, and timely access to mechanical thrombectomy can be life-saving. Indigenous solutions such as this directly strengthen India’s acute stroke care infrastructure.
Highlighting the clinical impact, Dr Mukesh Sharma, Principal Investigator of the Trial, Director, Neurointervention& Stroke, Marengo CIMS Hospital, said, “The GRASSROOT Trial is a game-changer for stroke care in India. High reperfusion rates with excellent safety mean more patients can now access life-saving mechanical thrombectomy within critical time windows, especially in resource-constrained settings.”
Dr R. Shankaran, Unit Medical Director, Marengo CIMS Hospital,added,“This study proves that world-class outcomes are achievable with indigenous innovation. It strengthens our confidence in delivering advanced stroke interventions that are timely, safe, and affordable for Indian patients.”
Emphasizing the broader cardiovascular ecosystem, Dr Keyur Parikh, Interventional Cardiologist and Chairman, Marengo CIMS Hospital, stated, “India urgently needs scalable, cost-effective solutions for complex vascular emergencies. The Supernova device and the GRASSROOT Trial represent exactly that — innovation driven by Indian clinical realities, backed by robust scientific evidence.”
Underscoring Marengo CIMS Hospital’s commitment to excellence, Dr RaajivSinghal, Founding Member, Managing Director and Group CEO. “At Marengo Asia Hospitals, our approach to innovation is grounded in patient outcomes, evidence, and real-world impact. This milestone reflects our patient-first philosophy and our collective commitment to advancing stroke care through robust, Indian clinical evidence. I compliment the clinicians, researchers, engineers, and partner institutions whose collaboration made this breakthrough possible. By teaching, training, and treating in equal measure, we are building a healthcare
ecosystem where excellence is sustainable, accessible, and firmly anchored in trust and outcomes.”
With India witnessing nearly 1.7 million new stroke cases annually, such indigenous, evidence-based innovations mark a critical milestone in strengthening the nation’s stroke care infrastructure — a mission Marengo CIMS Hospital continues to lead from the front.
